During the past decade, CTC North GmbH & Co. KG conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 6 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CTC North GmbH & Co. KG" #1 sponsor was "Universitätsklinikum Hamburg-Eppendorf" with 5 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Bayer" with 2 trials sponsored and "Idorsia Pharmaceuticals Ltd." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CTC North GmbH & Co. KG" #1 collaborator was "German Center for Infection Research" with 3 trials as a collaborator, "Clinical Trial Center North (CTC North GmbH & Co. KG)" with 2 trials as a collaborator, "Philipps University Marburg Medical Center" with 2 trials as a collaborator, "Albert Schweitzer Hospital" with 1 trials as a collaborator and "CR2O" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "CTC North GmbH & Co. KG" are "Healthy" (4 trials), "Hypertension" (2 trials), "Insomnia Disorder" (2 trials), "Alzheimer Disease" (1 trials) and "Atopic Dermatitis" (1 trials). Many other conditions were trialed in "CTC North GmbH & Co. KG" in a lesser frequency.

Most popular intervention types in "CTC North GmbH & Co. KG" are "Drug" (15 trials), "Biological" (6 trials), "Other" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Daridorexant 25 mg" (2 trials), "Daridorexant 50 mg" (2 trials), "Furosemide" (2 trials) and "Ad26.COV2.S" (1 trials). Other intervention names were less common.

The vast majority of trials in "CTC North GmbH & Co. KG" are 20 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CTC North GmbH & Co. KG". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in CTC North GmbH & Co. KG, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CTC North GmbH & Co. KG, 10 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".